International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2026
RSV vaccination in immunocompromised adults.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Loubet Paul, Fourati Slim, Launay Odile
Аннотация
BACKGROUND: Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract disease in immunocompromised adults, including solid organ and hematopoietic stem cell transplant recipients. Following the 2023 licensure of three RSV vaccines for older adults, increasing numbers of immunocompromised individuals have become eligible for vaccination, although these populations were largely excluded from pivotal phase 3 trials.
METHODS: We synthesize emerging data from prospective immunogenicity studies and large real-world effectiveness analyses evaluating RSV vaccines in immunocompromised adults.
RESULTS: Humoral immune responses are attenuated and heterogeneous, with seroconversion rates commonly ranging from 30-60% in transplant populations and strongly influenced by time since transplantation, lymphocyte counts, and exposure to antimetabolites such as mycophenolate. Despite reduced antibody responses, first-season vaccine effectiveness against hospitalization is generally between 65% and 75% in immunocompromised adults. Two-season analyses demonstrate waning protection, more pronounced than in immunocompetent individuals. Cellular immune responses, particularly CD4 T-cell responses, may be preserved despite diminished serologic responses, suggesting that antibody measurements alone may underestimate clinical protection.
CONCLUSION: Although immunogenicity is reduced and durability shorter than in immunocompetent adults, RSV vaccination provides meaningful protection against severe disease. Optimization of vaccination timing, booster strategies, and integration of passive immunization approaches warrant further study in high-risk subgroups.
METHODS: We synthesize emerging data from prospective immunogenicity studies and large real-world effectiveness analyses evaluating RSV vaccines in immunocompromised adults.
RESULTS: Humoral immune responses are attenuated and heterogeneous, with seroconversion rates commonly ranging from 30-60% in transplant populations and strongly influenced by time since transplantation, lymphocyte counts, and exposure to antimetabolites such as mycophenolate. Despite reduced antibody responses, first-season vaccine effectiveness against hospitalization is generally between 65% and 75% in immunocompromised adults. Two-season analyses demonstrate waning protection, more pronounced than in immunocompetent individuals. Cellular immune responses, particularly CD4 T-cell responses, may be preserved despite diminished serologic responses, suggesting that antibody measurements alone may underestimate clinical protection.
CONCLUSION: Although immunogenicity is reduced and durability shorter than in immunocompetent adults, RSV vaccination provides meaningful protection against severe disease. Optimization of vaccination timing, booster strategies, and integration of passive immunization approaches warrant further study in high-risk subgroups.